SHP2 Is Required for BCR-ABL1-Induced Hematologic Neoplasia

BCR-ABL1-targeting tyrosine kinase inhibitors (TKIs) have revolutionized treatment of Philadelphia chromosome-positive (Ph(+)) hematologic neoplasms. Nevertheless, acquired TKI resistance remains a major problem in chronic myeloid leukemia (CML), and TKIs are less effective against Ph(+) B-cell acut...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Shengqing, Sayad, Azin, Chan, Gordon, Yang, Wentian, Lu, Zhibin, Virtanen, Carl, Van Etten, Richard A., Neel, Benjamin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005183/
https://www.ncbi.nlm.nih.gov/pubmed/28804122
http://dx.doi.org/10.1038/leu.2017.250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005183/
https://www.ncbi.nlm.nih.gov/pubmed/28804122
http://dx.doi.org/10.1038/leu.2017.250

Ejemplares similares